Planar structural requirement at 4-position of 1-arylsulfonyl-4-phenyl-4,5-dihydro-2-imidazolones for their cytotoxicity

Archives of Pharmacal Research

Volumn 20, Issue 3, 1997, Pages 283-287

  Jung, Sang Hun ^a   Kwak, Suhk Jun ^a  

^a Chungnam National University   (South Korea)

Author keywords

4 Phenyl 1 arylsulfonylimidazolone; Cytotoxic activicity; Phenyl pharmacophore

Indexed keywords

EID: 0000377981     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02976159     Document Type: Article

References (19)

1. Everitt, E. and Wohlfart, C., Spectrophotometric quantitation of anchorage-dependent cell numbers extraction of naphthol blue-black-stained cellular protein. Anal. Biochem., 162(1), 122-9 (1987).
2. Grindey, G. B., Boder, G. B., Grossman, C. S., Howbert, J. J., Poore, G. A., Shaw, W. H., Todd, G. C., and Worzalla, J. F., Further development of diarglsulfonylureas as novel anticancer drugs. Proc. Am. Assoc. Cancer Res., 28, 309 (1987).
3. Grindey, G. B., Identification of diarysulfonylureas as novel anticancer drugs. Proc. Am. Assoc. Cancer Res., 29, 535 (1988).
4. Grindey, G. B., Current status of cancer drug development: Failure or limited success. Cancer Cells, 2, 163-171 (1990).
5. Hainsworth, J. D., Handle, K. R., Satterlee, W. G., Kuttesch, J., Johnson, D. H., Grindey, G. B., Jackson, L. E., and Greco, F. A., Phase I clinical study of N-[(4-chlorophenylamino)]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res., 49, 5217-5220 (1989).
6. Mansch, C., Leo, A., Exploring QSAR, ACS Professional Reference Book, American Chemical Society, Washington, DC, U. S. A., 1995, pp.522-528.
7. Houghton, P. J., Bailey, F. C., Germain, G. S., Grindey, G. B., Witt, B. C., and Houghton, J. A., N-(5-indahylsulfonyl)-N′-(4-chlorophenyl)-urea, A novel agent equally cytotoxic to nonproliferlating human colon adenosarcoma cells. Cancer Res., 50, 318-322 (1990).
8. Houghton, P. J., Bailey, F. C., Houghton, J. A., Murti, K. G., Howbert, J. J., and Grindey, G. B., Evidence for mitochondrial localization of N-(4-Methylphenylsulfonyl)-N′-(4-chlorophenyl) urea in human colon adenosarcoma cells. Cancer Res. 50, 664-668 (1990).
9. Howbert, J. J., Grossman, C. S., Crowell, T. A., Rieder, B. J., Harper, R. W., Kramer, K. E., Tao, E. V., Aikins, J., Poore, G. A., Rinzel, S. M., Grindey, G. B., Shaw, W. N., Todd, G. C., Novel Agents Effective against Solid Tumors: The Diarylsulfonylureas. Synthesis, Activities, and Analysis of Quantitative Structure-Activity Relationships. J. Med. Chem., 33, 2393-2407 (1990).
10. Howbert, J. J., Sulofenur. Drugs Future., 16, 517-520 (1991).
11. Jung, S. H., Song, J. S., Lee, H. S., Choi, S. U., and Lee, C. O., Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones. Bioorg. Med. Chem. Lett. 6, 2553-2558 (1996).
12. Jung, S. H., Song, J. S., Lee, H. S., Choi, S. U., and Lee, C. O., Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones containing sulfonylurea pharmacophore. Arch. Pharm. Res., 19, 570-580 (1996).
13. Kamthan, A., Scarffe, J. H., Walling, J., Hatty, S., Peters, B., Coleman, R., and Smyth, J. F., A phase II study of solufenur (LY186641) in gastric cancer. Anti-cancer Drugs, 3, 331-335 (1992).
14. Munshi, N. C., Seitz, D. E., Fosella, F., Lippman, S. N., and Einhorn, L. H., Phase Il study of sulofenur (LY186641). A novel antineoplastic agent in advanced non-small lung cancer. Proc. Am. Assoc. Cancer Res. 32, 189 (1991).
15. Perrin, D. D., Armarego, W. L. F., and Perrin, D. R., Purification of laboratory chemicals, 2nd edition. Pergamon Press, Oxford, England, 1982.
16. Schultz, R. M., Merriman, R. L., Toth, J. E., Zimmermann, J. E., Hertel, L. W., Andis, S. L., Dudley, D. E., Rutherford, P. G., Tanzer, L. R., and Crindey, G. B., Evaluation of new anticancer agents against the MIA Paca-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol. Res., 5, 223 (1993).
17. Skehan, P., Storeng, R., Scudiero, D. A., Monks, A., McMahon, J., Vista, D. T., Warren, J. T., Kenny, S., and Boyd, M. R., New Colorimetric cytotoxicity assay for anticancer drug screening, J. Natl. Cancer. Inst., 82, 1107-1112 (1990).
18. Talbot, D. C., Smith, I. E., Nicolson, M. C., Powles, T. J., Button, D., and Walling, J., Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer. J. Cancer Chemother. Pharmacol., 31, 419-422 (1993).
19. Taylor, C. W., Alberts, D. S., Ketcham, M. A., Satterlee, W. G., Holdsworth, M. T., Plazia, P. M., Peng, Y. M., Mccloskey, T. M., Roe, D. J., Hamilton, M., and Salmaon, S. E., Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J. Clin. Oncol., 7, 1733-1740 (1989).